Viral vectors for cancer immunotherapy

Frontiers in Bioscience

Volumn 11, Issue 1 P.447-888, 2006, Pages 804-817

  Harrop, Richard ^a   Carroll, Miles W ^b  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Cancer; Immunotherapy; Neoplasia; Review; Tumor; Tumor Antigen; Vaccine; Viral Vectors

Indexed keywords

EID: 32944473827     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1838     Document Type: Review

References (81)

1. W. Coley: Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases. Bull Johns Hopkins Hospital 7, 157 (1896)
2. P. Ehrlich: Uer den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneesk 53, 273-290 (1909)
3. E. J. Foley: Antigenic properties of methylcholanthrene-induced tumors in mice of the strain and origin. Cancer Res. 13, 835-837 (1953)
4. R. T. Prehn & J.M. Main: Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18, 769-778 (1957)
5. G. Klein, H. O. Sjogren, E. Klein & K. E. Hellstrom: Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561-1572 (1960)
6. A. B. Alexandroff & K. James: Immunotherapy of bladder cancer. In: Cancer Vaccines and Immunotherapy. Eds: P. L. Stern, P. C. L. Beverley & M. W. Carroll Cambridge University Press 19-46 (2000)
7. J. S. Ross, D. P. Schenkein, R. Pietrusko, M. Rolfe, G. P. Linette, J. Stec, N. E. Stagliano, G. S. Ginsburg, W. F. Symmans, L. Pusztai & G. N. Hortobagyi: Targeted therapies for cancer 2004. Am. J. Clin. Pathol. 122(4), 598-609 (2004)
8. D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga & L. Norton: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001)
9. A. D. Zelenetz: A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. Semin. Oncol. 30(2 Suppl 4), 22-30 (2003)
10. N. J. Nelson: Viruses and Cancer. J. Natl. Cancer Inst. 91(20), 1709 (1999)
11. M. Mackett, G. L. Smith & B. Moss: Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. Sci. 79, 7415-7419 (1982)
12. M. W. Carroll, G. Wilkinson & K. Lundstrom: Mammalian expression systems and vaccination. In: Genetically Engineered Viruses Eds. C. Ring & E. Blair BIOS Scientific Publishers Ltd Oxford, U.K. 107-158 (2001)
13. D. Panicali & E. Paoletti: Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vacinia virus. Proc. Natl. Acad. Sci. 79, 4927-4931 (1982)
14. M. W. Carroll & N. P. Restifo: Poxviruses as vectors for cancer immunotherapy. In: Cancer Vaccines and Immunotherapy. Eds P. L. Stern, P. C. L. Beverley & M. W. Carroll Cambridge University Press, 47-61 (2000)
15. J. M. Lane & J. D. Miller: Risks of smallpox vaccination complications in the United States. Am. J. Epidemiol. 93, 238-240 (1971)
16. J. Tartaglia, M. E. Perkus, J. Taylor, E. K. Norton, J. C. Audonnet, W. I. Cox, S. W. Davis, J. van der Hoeven, B. Meignier & M. Riviere: NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232 (1992)
17. G. Sutter & B. Moss: Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. 89, 10847-10851 (1992)
18. M. W. Carroll & B. Moss: Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propogation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology, 238, 198-211 (1997)
19. M. W. Carroll, W. W. Overwijk, R. S. Chamberlain, S. A. Rosenberg, B. Moss & N. P. Restifo: Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15(4), 387-394 (1997)
20. G. Antoine, F. Scheiflinger, F. Dorner & F. G. Falkner: The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244(2), 365-396 (1998)
21. G. L. Smith, J. A Symons, A. Khanna, A. Vanderplasschen & A. Alcami: Vaccinia virus immune evasion. Immunological Reviews 159, 137-154 (1997)
22. th Annual Conference of FOCIS 459-464 (2004)
23. D. M. Goldenberg, R. M. Sharkey & F. J. Primus: Carcinoembryonic antigen in histopathology: immunoperoxidase staining of conventional tissues sections. J. Natl. Cancer Inst. 57, 11-22 (1976)
24. J. W. Hodge, H. Sabzevari, A. G. Yafal, L. Gritz, M. G. Lorenz & J. Schlom: A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59(22), 5800-5807 (1999)
25. J. M. Hamilton, A. P. Chen & B. Nguyen: Phase I study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas. Proc. Am. Soc. Clin. Oncol. 13, 961-969 (1995)
26. R. M. Conry, M. B. Khazaeli, M. N. Saleh, K. O. Allen, D. L. Barlow, S. E. Moore, D. Craig, R. B. Arani, J. Schlom & A. F. LoBuglio: Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administration. Clin. Cancer Res. 5, 2330-2337 (1999)
27. M. G. Sanda, D. C. Smith, L. G. Charles, C. Hwang, K. J. Pienta, J. Schlom, D. Milenic, D. Panicali & J. E. Montie: Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53(2), 260-266 (1999)
28. J. P. Eder, P. W. Kantoff, K. Roper, G. X. Xu, G. J. Bubley, J. Boyden, L. Gritz, G. Mazzara, W. K. Oh, P. Arlen, K. Y. Tsang, D. Panicali, J. Schlom & D. W. Kufe: A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 6(5), 1632-1638 (2000)
29. S. M. Scholl, J. M. Balloul, G. Le Goc, N. Bizouarne, C. Schatz, M. P. Kieny, S. von Mensdorff-Pouilly, A. Vincent-Salomon, L. Deneux, E. Tartour, W. Fridman, P. Pouillart & B. Acres: Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. 23, 570-580 (2000)
30. C. Rochlitz, R. Figlin, P. Squiban, M. Salzberg, M. Pless, R. Herrmann, E. Tartour, Y. Zhao, N. Bizouarne, M. Baudin & B. Acres: Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 5(8), 690-699 (2003)
31. N. Hole & P. L. Stern: A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br. J. Cancer 57, 239-246 (1988)
32. K. A. Myers, V. Rahi-Saund, M. D. Davison, J. A. Young, A. J. Cheater & P.L. Stern. Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. J. Biol. Chem. 269, 9319-9324 (1994)
33. T. Starzynska, P. J. Marsh, P. F. Schofield, S. A. Roberts, K. A. Myers & P. L. Stern: Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br. J. Cancer 69, 899-902 (1994)
34. M. W. Carroll, R. Harrop, N. Connolly, I. Redchenko, M. Ryan, N. Drury, M. Kelleher, S. Kingsman & R. Hawkins: Modified Vaccinia Ankara (MVA) expressing the tumour associated antigen 5T4 (TroVax) induces immune responses in late stage colorectal cancer patients in a phase I/II clinical trial. Proceedings of the American Association for Cancer Research Annual Meeting (2004) Abstract
35. J. L. Marshall, R. J. Hoyer, M. A. Toomey, K. Faraguna, P. Chang, E. Richmond, J. E. Pedicano, E. Gehan, R. A. Peck, P. Arlen, K. Y. Tsang & J. Schlom: Phase I study in advanced cancer patients of a diversified prime- and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. 18(23), 3964-3973 (2000)
36. H. L. Kaufman, W. Wang, J. Manola, R. S. DiPaola, Y. J. Ko, C. Sweeney, T. L. Whiteside, J. Schlom, G. Wilding & L.M. Weiner: Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin. Oncol. 22(11), 2122-2132 (2004)
37. S. A. Rosenberg, J. C. Yang, D. J. Schwartzentruber, P. Hwu, S. L. Topalian, R. M. Sherry, N. P. Restifo, J. R. Wunderlich, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. A. Mavroukakis, L. Gritz, D. L. Panicali & D. E. White: Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate immune responses in patients with metastatic melanoma. Clin. Cancer Res. 9, 2973-2980 (2003)
38. J. L. Marshall, M. J. Hawkins, K. Y. Tsang, E. Richmond, J. E. Pedicano, M. Zhu Zhu & J. Schlom: Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin Oncol. 17(1), 332-337 (1999)
39. M. Z. Zhu, J. Marshall, D. Cole, J. Schlom & K. Y. Tsang: Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. 6, 24-33 (2000)
40. M. von Mehren, P. Arlen, K. Y. Tsang, A. Rogatko, N. Meropol, H. S. Cooper, M. Davey, S. McLaughlin, J. Schlom & L. M. Weiner: Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6(6), 2219-2228 (2000)
41. M. von Mehren, P. Arlen, J. Gulley, A. Rogatko, H. S. Cooper, N. J. Meropol, R. K. Alpaugh, M. Davey, K. Y. Tsang, J. Schlom & L. M. Weiner: The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7, 1181-1191 (2001)
42. H. Horig, D. S. Lee, W. Conkright, J. Divito, H. Hasson, M. LaMare, A. Rivera, D. Park, J. Tine, K. Guito, K. Wong-Yok, J. Schlom & H. L. Kaufman: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. 49, 504-514 (2000)
43. M. Everts & D. T. Curiel: Transductional targeting of adenoviral cancer gene therapy. Curr. Gene Ther. 4(3), 337-346 (2004)
44. R. L. Chu, D. E. Post, F. R. Khuri & E. G. Van Meir: Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 10(16), 5299-5312 (2004)
45. D Oosterhoff & V. W. van Beusechem: Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy. J. Exp. Ther. Oncol. 4(1), 37-57 (2004)
46. J. L. Imler: Adenovirus vectors as recombinant viral vaccines. Vaccine 13, 1143-1151 (1995)
47. S. K. Basak, S. M. Kiertscher, A. Harui & M. D. Roth: Modifying adenoviral vectors for use as gene-based cancer vaccines. Viral Immunol. 17(2), 182-196 (2004)
48. S. A. Rosenberg, Y. Zhai, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, C. A. Seipp, J. H. Einhorn, B. Roberts & D. E. White: Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Can. Inst. 90(24), 1894-1900 (1998)
49. J. H. Strauss & E. G. Strauss: The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58, 491-562 (1994)
50. S. Loimas, M. R. Toppinen, T. Vasakoppi, J. Janne & J. Wahlfors: Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy. Cancer Gene Ther. 8, 137-144 (2001)
51. C. Asselin-Paturel, U. Lassau, J-M. Guinebretiere, J. Zhang, F. Gay, F. Bex, S. Hallez, J. Leclere, P. Peronneau, F. Mami-Chouaib & S. Chouaib: Transfer of the murine interleukin-12 gene in vivo by a Semliki forest virus vector induces B16 tumor regression through inihibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther. 6, 606-615 (1999)
52. A. H. Klimp, E. van der Vaart, P. O. Lansink, S. Withoff, E.G. de Vries, G. L. Scherphof, J. Wilschut & T. Daemen: Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF. Gene Ther. 8, 300-307 (2001)
53. T. Daemen, J. Regts, M. Holtrop & J. Wilschut: Immunization strategy against cervical cancer involoving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Therapy 9, 85-94 (2002)
54. K. S. Wang, R. J. Kuhn, E. G. Strauss, S. Ou & J. H. Strauss: High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J. Virol. 66, 4992-5001 (1992)
55. S. Martignone, S. Menard, R. Bufalino, N. Cascinelli, R. Pellegrini, E. Tagliabue, S. Andreola, F. Rilke & M. I. Colnaghi: Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J. Natl. Cancer Inst. 85, 398-402 (1993)
56. X. Sanjuan, P. L. Fernandez, R. Miquel, J. Munoz, V. Castronovo, S. Menard, A. Palacin, A. Cardesa & E. Campo: Overexpression of the 67-kD laminin receptor correlates with tumor progression in human colorectal cancer. J. Pathol. 179, 376-380 (1996)
57. J. C. Tseng, B. Levin, A. Hurtado, H. Yee, I. Perez de Castro, M. Jimenez, P. Shamamian, R. Jin, R. P. Novick, A. Pellicer & D. Meruelo: Systemic tumor targeting and killing by Sindbis viral vectors. Nat. Biotech. 22(1), 70-77 (2004)
58. J. C. Tseng, A. Hurtado, H. Yee, B. Levin, C. Boivin, M. Benet, S. V. Blank, A. Pellicer & D. Meruelo: Using Sindbis viral vectors for specific detection and supporession of advanced ovarian cancer in animal models. Cancer Res. 64, 6684-6692 (2004)
59. E. L. Nelson, D. Prieto, T. G. Alexander, P. Pushko, L. A. Lofts, J. O. Rayner, K. I. Kamrud, B. Fralish & J. F. Smith: Venzuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self tumor-associated antigen, neu in a rat mammary tumor model. Breast Cancer Res. Treat. 82(3), 169-183 (2003)
60. W. W. Leitner, L. H. Hwang, M. J. De Veer, A. Zhou, R. H. Silverman, B. R. G. Williams, T. W. Dubensky, H. Ying & N. P. Restifo: Alphavirus based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med 9(1), 33-39 (2003)
61. C. A. Bolovan, N. M. Sawtell & R. L. Thompson: ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J. Virol. 68, 48-55 (1994)
62. J. Chou & B. Roizman: The γ 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc. Natl. Acad. Sci. (USA) 89, 3266-3270 (1992)
63. E. A. McKie, A. R. MacLean, A. D. Lewis, G. Cruickshank, R. Rampling, S. C. Barnett, P. G. Kennedy & S. M. Brown: Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumors: evaluation of a potentially effective clinical therapy. Br. J. Cancer 74, 745-752 (1996)
64. R. Rampling, G. Cruickshank, V. Papanastassiou, J. Nicoll, D. Hadley, D. Brennan, R. Petty, A. MacLean, J. Harland, E. McKie, R. Mabbs & M. Brown: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859-866 (2000)
65. J. M. Markert, M. D. Medlock, S. D. Rabkin, G. Y. Gillespie, T. Todo, W. D. Hunter, C. A. Palmer, F. Feigenbaum, C. Tornatore, F. Tufaro & R. L. Martuza: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7, 867-874 (2000)
66. X. Fu & X. Zhang: Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res. 62, 2306-2312 (2002)
67. H. Kasuya, T. M. Pawlik, J. T. Mullen, J. M. Donahue, H. Nakamura, S. Chandrasekhar, H. Kawasaki, E. Choi & K. K. Tanabe: Selectivity of an oncolytic Herpes Simplex Virus for cells expressing the DF3/MUC1 antigen. Cancer Res. 64, 2561-2567 (2004)
68. M. Toda, R. L. Martuza, H. Kojima & S. D. Rabkin: In situ vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160, 4457-4464 (1998)
69. R. J. Parkinson, S. Mian, M. C. Bishop, T. Gray, G. Li, S. E. McArdle, S. Ali & R. C. Rees: Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy. Prostate 56(1), 65-73 (2003)
70. P. T. Loudon, C. S. McLean, G. Martin, J. Curry, M. Leigh Shaw, C. Hoogstraten, E. Verdegaal & S. Osanto: Preclinical evaluation of DISC-GMCSF for the treatment of breast carcinoma. J. Gene Med. 5(5), 407-416 (2003)
71. K. W. Reichard, R. M. Lorence, C. J. Cascino, M. E. Peeples, R. J. Walter, M. B. Fernando, H. M. Reyes & J. A. Greager: Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 52(5), 448-53 (1992)
72. A. L. Pecora, N. Rizva, G. I. Cohen, N. J. Meropol, D. Stermna, J. L. Marshall, S. Goldberg, P. Gross, J. D. O'Neil, W. S. Groene, M. S. Roberts, H. Rabin, M. K. Bamat & R. M. Lorence: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20(9), 2251-2266 (2002)
73. J. Karcher, G. Dyckhoff, P. Beckhove, C. Reisser, M. Brysch, Y. Ziouta, B. H. Helmke, H. Weidauer, V. Schirrmacher & C. Herold-Mende: Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 64, 8057-8061 (2004)
74. N. J. Nelson: Scientific interest in Newcastle disease virus is reviving. J. Natl. Cancer Inst 91(20), 1708-1710 (1999)
75. C. T. Lin, C. F. Hung, J. Juang, L. He, K. Y. Lin, T. W. Kim & T. C. Wu: Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol. Ther. 8(4), 559-566 (2003)
76. C. L. Smith, P. R. Dunbar, F. Mirza, M. J. Palmowski, D. Shepherd, S. C. Gilbert, P. Coulie, J. Schneider, E. Hoffman, R. Hawkins, A. L. Harris & V. Cerundolo: Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer 113(2), 259-266 (2005)
77. J. W. Hodge, J. P. McLaughlin, J. A. Kantor & J. Schlom: Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15(6/7), 759-768 (1997)
78. J. W. Hodge, D. J. Poole, W. M. Aarts, A. G. Yafal, L. Gritz & J. Schlom: Modified Vaccinia Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 15, 7942-7949 (2003)
79. S. A. Rosenberg, J. C. Yang & N. P. Restifo: Cancer Immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004)
80. S. Mocellin, S. Mandruzzato, V. Bronte, M. Lise & D. Nitti: Part I: Vaccines for solid tumours. Lancet Oncol. 5(11), 681-689 (2004)
81. J. Gulley, A. P. Chen, W. Dahut, P. M. Arlen, A. Bastian, S. M. Steinberg, K. Tsang, D. Panicali, D. Poole, J. Schlom & J. M. Hamilton: Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53(2), 109-117 (2002)